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Abstract
Background: Most malignant lymphomas in HIV-patients are caused by reactivation of EBV-infection. Some
lymphomas have a very rapid fulminant course. HHV-8 has also been reported to be a cause of lymphoma. The role
of CMV in the development of lymphoma is not clear, though both CMV and HHV-8 have been reported in tissues
adjacent to the tumour in Burkitt lymphoma patients. Here we present a patient with asymptomatic HIV infection,
that contracted a primary cytomegalovirus (CMV) infection and human herpes virus 8 (HHV-8) infection. Three
weeks before onset of symptoms the patient had unprotected sex which could be possible source of his CMV and
also HHV-8 infection He deteriorated rapidly and died with a generalized anaplastic large cell lymphoma (ALCL).
Methods: A Caucasian homosexual male with asymptomatic human immunodeficiency virus (HIV) infection
contracted a primary cytomegalovirus (CMV) infection and human herpes virus 8 (HHV-8) infection. He deteriorated
rapidly and died with a generalized anaplastic large cell lymphoma (ALCL). Clinical and laboratory records were
compiled. Immunohistochemistry was performed on lymphoid tissues, a liver biopsy, a bone marrow aspirate and
the spleen during the illness and at autopsy. Serology and PCR for HIV, CMV, EBV, HHV-1–3 and 6–8 was performed
on blood drawn during the course of disease.
Results: The patient presented with an acute primary CMV infection. Biopsies taken 2 weeks before death showed
a small focus of ALCL in one lymph node of the neck. Autopsy demonstrated a massive infiltration of ALCL in
lymph nodes, liver, spleen and bone marrow. Blood samples confirmed primary CMV- infection, a HHV-8 infection
together with reactivation of Epstein- Barr-virus (EBV).
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Conclusion: Primary CMV-infection and concomitant HHV-8 infection correlated with reactivation of EBV. We
propose that these two viruses influenced the development and progression of the lymphoma. Quantitative PCR
blood analysis for EBV, CMV and HHV-8 could be valuable in diagnosis and treatment of this type of very rapidly
developing lymphoma. It is also a reminder of the importance of prevention and prophylaxis of several infections
by having protected sex.
Keywords: Primary CMV-infection, EBV latency, HHV-8 infection, Malignant lymphoma, ALCL, CMV-DNA, EBV-DNA,
HHV-8 DNA, Unprotected sex
Background
Cytomegalovirus (CMV) often causes lethal complications
in patients with advanced HIV-infection [1, 2]. As the ma-
jority of HIV-infected patients are CMV-seropositive at
the time of seroconversion little is known about primary
CMV infection in HIV-patients with or without severe
immunodeficiency. Recently two case reports have been
published [3, 4]. The first case was a pregnant HIV posi-
tive woman on antiretroviral therapy, who was diagnosed
with primary CMV-infection after 30 weeks gestation. She
was treated with intravenous ganciclovir iv for a week and
thereafter valacyclovir orally until the end of pregnancy.
She was CMV-PCR negative after 4 weeks treatment, and
delivered after 37 weeks’ gestation a small child (2.07 kg)
in whom a prenatal CMV infection could be ruled out.
The second case was a probable primary co- infection
with HIV and CMV. A 25-year-old Caucasian male devel-
oped meningitis, hepatitis, myelopathy in the legs and ret-
inal cotton wool spots at examination of the eyes but no
CMV-retinitis. He was treated with combination anti-
retroviral therapy (c-ART) for the HIV-infection. During
10 weeks he developed IgG and IgM antibodies to CMV,
HIV-RNA in the blood was 386 000 copies and CMV-
PCR was 690 copies/ml. The CD4 count was 801 × 106/L.
He improved upon continued c-ART, even if he did not
receive CMV-treatment. However the authors conclude
that the overlapping manifestations of acute HIV-1 and
CMV makes it difficult to determine how each virus infec-
tion contributed to his condition. None of these primary
CMV-infection cases were associated with lymphoma or
other tumour development. That CMV might be involved
in the development of PTLD has been suggested [5].
Epstein-Barr-virus (EBV) is related to several types of ma-
lignant lymphomas, especially in HIV-infected patients,
and also to post-transplant lymph proliferative disorder
(PTLD) [5, 6]. HHV-8 is linked to Kaposi’s sarcoma,
Castleman’s disease and to some lymphomas [7]. One
HHV-8 associated ALCL has been documented in a HIV-
positive patient [8]. In this patient there was no sign of
EBV in the tumour but EBV-reactivation and CMV infec-
tion was not investigated. A malignant lymphoma in an
HIV-positive patient with EBV and HHV-8 co infection
has recently been described by Crane et al. [9]. This
patient died within 3 months of diagnosis of the lymph-
oma. An ALCL with very rapid progression has also been
described by Mosunjac et al. [10]. The development of
HHV-8 infection is not as well described as the infection
with the other human herpes viruses. Hladik et al. [11]
studied serocorversion time after blood transfusion and
found that most HHV-8 negative patients serocorverted
in three to ten weeks after transfusion with HHV-8 sero-
positive blood. Similar seroconvertion times was also
found by Sergeric et al and Gentile at al in patients after
Bone Marrow Transplantation [12, 13]. Two cases of fatal
disseminated Kaposi’s sarcoma following HHV-8 primary
infections has been described by Marcelin et al. [14]. They
died at 5 and 6 months after transplantation after a disease
course of 3 to 4 weeks. Abate et al. [15] recently demon-
strated other human herpes viruses than EBV in eight
patients with Burkitt lymphoma. They found four patients
with CMV in the adjacent non-neoplastic tissue, three with
HHV-8 and in one patient EBV, CMV, HHV-8 and HTLV-
1 was found simultaneously. All viruses were detected by
immunohistochemistry and they suggest that these viruses
might be a contributing factor to lymphoma development.
Here we present an asymptomatic HIV-infected
Caucasian homosexual male with a primary CMV-
infection, HHV-8 infection and concomitant reactiva-
tion of EBV, who developed a malignant lymphoma
leading to death within 3 weeks.
Results
Clinical report
A 34-year old HIV-infected man presented acutely due
to a 2 days’ period of fatigue and fever. Two years earlier
he had been diagnosed with HIV-infection as a result of
screening for sexually transmitted infections (STI). At
the time of HIV-diagnosis he was in good health but
with slightly enlarged neck lymph nodes. He was sero-
negative for hepatitis A, C and CMV, but had IgG anti-
bodies to EBV and was seropositive for hepatitis B
surface antigen and e-antigen. Liver enzymes were
normal. As he was asymptomatic with a CD4 cell
count > 500 × 106/L, he was followed up clinically but
without antiretroviral medication. One year later the
CD4 count still was >500 × 106/L.
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On acute admission, the patient had enlarged lymph
nodes in the neck and axillae. There was no palpable
hepatic or spleen enlargement, but he had a slight pain
upon examination of the left side of the abdomen.
Auscultation of the heart and lungs was normal. After
hospitalization the fever and malaise continued and in
three days he had a massive enlargement of lymph nodes
on both sides of the neck and in the axillae. The spleen
was now palpable five centimetres below the left arc of
the ribs and the liver 1–2 cm below the right arc. An op-
portunistic infection was suspected already day one but
diagnostic tests for sepsis, tuberculosis, other mycobac-
terial infections, and Pneumocystis jiroveci (carinii)
pneumonia were negative. Chest X-ray showed no ab-
normalities. The CD4 cell count was 540 × 106/L and
his plasma HIV-RNA level was 31 000 copies/mL. An
enlarged liver and spleen (15,5 × 8 cm) were confirmed
by computer tomography. The histopathology of a lymph
node removed from the left side of the neck was inter-
preted as reactive hyperplasia without signs of lymphoma.
Bone marrow aspirate and liver biopsy showed reactive in-
flammation without signs of lymphoma or other malig-
nancies. There were no signs of infections with CMV,
mycobacterium or fungi.
Progress and CMV-testing
The course of the disease with fever, blood parameters
and date of biopsies are shown in Fig. 1. C-reactive
protein (CRP) was moderately increased upon admission
and did not change during the first 2 weeks. The patient
had leucocytosis due to the increase of both neutrophils
and lymphocytes and from day three until day 14 he had
a pronounced lymphocytosis including activated lym-
phocytes microscopically resembling Downey- McKinley
cells observed in patients with primary EBV- and CMV-
infection. The majority of the lymphocytes (75 %) were
T-cells. The CD4 cells increased from 550 × 106/L to
1240 × 106/L and the CD8s from 1390 × 106/L to 2970 ×
106/L, while the ratio was unchanged (0.4) compared to
the year before. CMV was identified by PCR and by a
rapid isolation technique [16] of peripheral blood leuco-
cytes on day three, providing a working diagnosis of a pri-
mary CMV-infection. Because of the fever a 3-day
treatment with indomethacin was initiated on day 18,
upon which the temperature decreased, but then reap-
peared on day 21.
Since the patient rapidly deteriorated with cerebral
confusion, declining haemoglobin and platelets, treat-
ment with foscarnet was initiated intravenously at
90 mg/kg twice daily on day 22. After 12 h the
temperature normalised and the patient felt better. How-
ever, during the next 24 h the patient’s condition deteri-
orated and he died.
Autopsy showed Adult Respiratory Distress Syndrome
(ARDS) and massive lymphoma infiltration in liver,
spleen and multiple lymph nodes, which motivated a
re-evaluation of the course of the disease and the
potential role of herpes viruses in the development
of the disease.
Detection of CMV, EBV and HHV-8
Serum and plasma samples were analyzed for CMV IgG
and IgM, EBV IgG and IgM, HHV-8 IFT (antibodies
against lytic antigens) and HHV-8 LANA (late nuclear
Fig. 1 Overview of the in-patient history: temperature curve, blood cell parameters and Creactive protein. The continuous red line is the
temperature curve. The red arrows above the curve indicate time points for CMV-, EBV- and HHV-8 serology and/or PCR. The long black arrows
beneath show time points from left to right for lymph node biopsy, liver biopsy and bone marrow aspiration. HB = Haemoglobin in g/L, PLT = Platelet
count x 1012/L, WBC =white blood cell count x 109/L, LC = lymphocyte count x 109/L, C-reactive protein in mg/L
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antigen) antibodies (Table 1), as well as CMV-DNA,
EBV-DNA, HHV-8-DNA and HIV-RNA (Table 2).
Furthermore, the samples were tested for antibodies and
PCR for herpes simplex virus (HSV) 1, 2 as well as Varicella
Zoster Virus (VZV) and HHV-6, -7. The patient, earlier
seronegative, had increasing CMV-IgG and -IgM during
the disease.
CMV-PCR increased as well during the acute disease.
The patient had EBV antibodies before the acute disease
which did not change significantly during the acute dis-
ease. EBV-DNA, negative the year before his acute dis-
ease, increased during the last 2 weeks. The patient was
HHV-8 sero- and PCR negative the year before acute
disease. He presented with a positive HHV-8 serostatus
(antibodies to lytic antigen) at day three of the acute dis-
ease but the HHV-8 LANA antibodies were negative
throughout the disease His HHV-8 DNA load however
increased during his disease from undetectable on day
three to 54000 copies/mL on day 21 (Tables 1 and 2).
The HIV-RNA levels were unchanged compared to the
previous year. HIV-1 was shown to be of subtype B and
of the R5 co receptor use/phenotype. HSV 1 and 2, VZV,
HHV-6 and HHV-7 measured with PCR in blood were
negative throughout the disease. There were no change
in IgG of the other herpes viruses investigated (HSV1-2,
VZV, HHV-6 and 7.)
Morphologic, immonohistochemical and flow cytometric
analysis
Tissue samples from lymph node, liver and bone marrow
biopsies, and post mortem samples were stained with
hematoxylin and eosin, according to standard protocols.
(EBER) by an in situ hybridization technique (Dakopatts)
was performed on biopsies and autopsy material. At
autopsy the patient macroscopically had an enlarged liver
and spleen. Enlarged lymph nodes were found in the
mediastinum, the abdomen and adjacent to the liver. All
other organs, including the brain, were normal. Micro-
scopic examination showed that the lung alveoli were
filled with fluid that can be observed in ARDS. The lymph
nodes, bone marrow, and spleen showed infiltration by a
large cell malignant lymphoma. The lymphoma at autopsy
was analysed using a streptavidin-biotin procedure with
monoclonal antibodies against the following cellular dif-
ferentiation (CD) antigens: CD20, CD79e, CD2, CD3,
CD4, CD5, CD7, CD8, CD30, CD15, and also the ALCL
markers ALK-1 and Ki-67, showing immune profile con-
sistent with CD30-positive ALK-1 negative ALCL Immu-
nohistochemistry showed an immune profile consistent
with CD30-positive ALK-1 negative ALCL (Table 3 and
Fig. 2).
Immunohistochemistry for CMV was negative. There
were no spindle cells typical of Kaposi’s sarcoma in the
lymphoma or adjacent tissue. There was no sign of hae-
matophagocytic histiocytosis in the bone marrow.
Discussion
This is the first report of a malignant lymphoma with
signs of reactivation of EBV concomitant with both
primary CMV-infection and HHV 8 infection in an HIV
infected patient. The lymphoma was diagnosed as ALCL.
To our knowledge this is the first report of a lethal
primary CMV-infection in an HIV-infected patient with
a well-preserved immune system. The HHV-8 infection
was verified by seroconversion and increasing levels of
HHV-8 PCR in blood and could be a contributing
factor.
Autopsy showed that the immediate cause of death
was ARDS, which is reported to occur during primary
CMV-infection and in patients with severe malignancies
[17, 18]. Contributing to the cause of death was the
massive infiltration of ALCL cells in bone marrow,
lymph nodes, and spleen. Before the acute illness there
were no signs or symptoms of generalised lymphoma.
Three weeks before onset of symptoms the patient had
unprotected sex which could be possible source of his
CMV and also HHV-8 infection. The absence of CMV
IgM and IgG antibodies early during the acute illness in
combination with the seroconversion after 1 week, sup-
port the diagnosis of a primary CMV infection. The
detection of CMV by virus isolation, rapid isolation, and
by PCR [19], concomitant with the detection of viral
DNA in plasma confirmed that the patient experienced
a primary CMV infection (Table 1). Furthermore, the
significant increase in CD4 and CD8 lymphocytes is
compatible with such a primary infection [20]. The sero-
conversion for HHV-8 and the rapid HHV 8-DNA in-
crease is consistent with active ongoing infection. The
patient was probably infected at the same time as when
Table 1 Serological analysis of CMV, EBV and HHV-8 antibodies
over time
Test used 9 months prior
to admission
Day 3 Day 10 Day 21
CMV IgG EIA <100a < 100a 500b 1000b
CMV-IgM capture EIA <100a < 100a 100b Close to
cut-offa












EIA enzyme immunosorbent assay, VCA viral capsid antigen
anegative
bpositive
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he was infected by CMV. The seroconversion time for
HHV-8 is similar to the other herpes viruses [11]. The
HHV-8 LANA antibodies was negative throughout his
disease but this method is not as sensitive as the HHV-8
IFT test [14]. The earlier reports on primary CMV-
infection in HIV-patients have not been linked with
lymphoma nor with an aggressive and lethal course.
Two previously reported cases had been treated with
antiretroviral therapy [3, 4]. One was treated with gancy-
clovir for the CMV infection and responded with a rapid
resolution of symptoms. The other had a protracted
course, but the role of CMV could not be evaluated, be-
cause the symptoms could equally well be due to the
concomitant primary HIV infection.
In this case CMV-PCR in blood was only slightly ele-
vated in contrast to our patient. These two patients were
not analysed for EBV, HHV 8 or other herpes viruses.
Our patient’s latent EBV-infection was reactivated
shown by the increasing EBV-DNA levels in serum [21]
and EBER was detected in lymphocytes EBV is associ-
ated with many forms of malignant lymphoma in AIDS
patients including the CNS-NH lymphomas which are
100 % EBV-associated [22]. While severe CMV-related
CNS disease is often found in AIDS cases, CMV has
rarely been found to be directly associated with CNS
lymphomas, except in one study, where CMV inclusions
were found in the cerebral neoplastic cells [23]. CMV is
also connected to EBV-initiated post-transplant lymph
proliferative disease (PTLD) in patients after transplanta-
tions with bone marrow or solid organs [5, 6] related to
the immunosuppressive therapy. A direct relationship
between a primary CMV-infection, EBV reactivation and
ALCL or other lymph proliferative disorders, such as
PTLD, has not been reported. However the presence of
CMV together with HHV-8 in the EBV driven endemic
Burkitt lymphoma recently observed indicate a possible
role for other herpes viruses than EBV in the develop-
ment of lymphomas. In a few cases of early primary effu-
sion Lymphoma (PEL) the neoplastic cells have shown
to be co infected with EBV and HHV-8 [24]. The ALCL
is considered to be a T-Cell derived lymphoma but asso-
ciation with EBV or HHV-8 has only been reported in a
few cases [7]. In the chronic stage HIV-infection can
interfere with the immune system at many levels that
will facilitate tumour development (oncogenesis) as well
as CMV infection. CMV was not found in the lymph-
oma cells but can also facilitate tumour development by
interfering with the immune system. Crane et al. [9] re-
port on a co infection with EBV and HHV-8 in a vascu-
lar ALCL in an HIV positive patient with well preserved
immune system. This patient got c-ART and had a CD4
count above 500. Co-infection with EBV and HH-8 in
Table 2 Detection of CMV, EBV, and HIV in blood samples over time
Test used 9 months priora) to admission Day 3a) Day 10b) Day 21a)
CMV-isolation, classical and rapid Positive
Quantitative CMV-DNA in plasma/serum (copies/mL) Negative 3700 6000 2700
Quantitative EBV-DNA in plasma/serum (copies/mL) Negative 250 520 5600
Quantitavie HHV-8-DNA In plasma/serum (copies/mL) Negative Negative 11000 54000
Quantitative HIV-RNA in plasma/serum (copies/mL) 30,000 31000 27000
a)tested in serum
b)tested on EDTA-blood
Table 3 Results of immunohistochemistry











CD30 ALCL cells positive positive
LMP1 negative
EBER Some positive negative
CD 57 negative
K-1 positive
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this patient was detected using situ hybridisation for
EBER and HHV-8.
Our patient had evidence of five viral infections HIV,
chronic HBV, latent EBV and primary CMV and HHV-8.
All of these five viruses can have contributed to the de-
velopment of the lymphoma. During the course of the
disease we have seen a rapid increase in CMV-DNA,
EBV-DNA and HHV-8 DNA in the blood simultan-
eously with the development of the lymphoma support-
ing the earlier findings, that both EBV and HHV-8 could
be involved in the tumor development. However neither
HIV-RNA levels, nor the CD4/CD8 ratio changed during
the course of the disease, implying that the HIV-
infection was not directly influenced by the reactivation
of the EBV-infection or the development of the lymph-
oma. However, the HIV-infection might have caused an
immunodeficiency that contributed to the tumour devel-
opment. HBV has only been associated with hepatocellu-
lar cancer as an effect of the chronic inflammation in
the liver. There is no increased risk of haematological
malignancies in HIV-patients with chronic hepatitis B
compared to other HIV-infected patients as shown by
Jou et al. [25]. HHV-8 infects dendrite cells and B cells
[26]. HHV-8 show a very particular protein profile in
latency, that has not been identified in other herpes
viruses, or viruses in general [27]. During active replica-
tion viral IL6, IRF-, IRF-3, K1 and K15 are expressed
maximally but they are also detected subsequently in the
latent cells. IL6 is a powerful inducer of inflammation
and might affect EBV- reactivation, HHV-8 infection or
primary CMV infection and even contribute to onco-
genic process. The complex interactions of HIV, CMV
and HHV-8- and even HBV could have provided the ne-
cessary combination of immune suppression and im-
mune stimulation for the lymphoma genesis to precede
and accelerate, even though the HIV-infection was not
advanced, as measured by HIV-RNA and CD4 counts.
We found no primary infection or reactivation of the
other human herpes viruses investigated (HSV-1 and 2,
VZV, HHV-6 and 7) in this patient. A rapid course
(weeks to a few months) of ALCL in a subset of patients
has been reported [10]. However, in these patients the
development and role of CMV, EBV and HHV8 was not
investigated. It would have been interesting to know if
Fig. 2 a Histopathology of a lymph node at autopsy, showing ALCL. The inset shows enlargement of tumour cells. b ALCL Magnification x 20.
c CD30 immunohistochemestry positive. d Ki-67 immunohistochemestry positive
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rapid lymphoma progression in these patients was corre-
lated to reactivation of CMV, EBV, HHV8 or other vi-
ruses. Furthermore, the increase in EBV-DNA, HHV8-
DNA in blood that was found in our patient during the
cause of the disease might be used as an indicator of the
severity of the lymphoma that is under development in a
patient with an unclear lymphoproliferative disorder and
might also be of help when evaluating the therapeutic re-
sponse for this lymphoma as has been suggested earlier
[28]. It is relevant to look for more than one virus having
a role in lymphoma development with both serology and
PCR-techniques, especially if you have an unusually rapid
progression of the lymphoma. If CMV-PCR increases as a
sign of developing CMV-infection treatment with gancy-
clovir should be started immediately to prevent further
deterioration caused by CMV-infection. If both CMV and
HHV-8 DNA are discovered foscarnet could also be used.
There is a need for optimal and early anti-CMV treatment
in patients with HIV infection and a primary CMV infec-
tion as well as HHV-8 treatment if HHV-8 infection is
found. Today there is no good viral prophylaxis against
CMV or HHV-8 infection but there is hope of a CMV-
vaccine in the future. This case story is also an example of
the hazard of having unprotected sex without condoms.
The risk is for all HIV-infected patients, especially if the
patient is CMV-seronegative.
Another issue is the need for specially designed cyto-
static therapy for these lymphomas that seem to have a
very poor prognosis compared to others. In our index
patient the CMV treatment was introduced rather late
and this might have been suboptimal to the outcome.
Limitations of this study is that we have not investigated
HBV in the lymphoma and that in situ hybritization for
HHV 8 in the histology of the lymphoma failed.
Conclusions
The rapid lymphoma development in our patient, together
with the kinetics of the laboratory and pathological find-
ings over a short period of time provide a conspicuous
link between the three herpes virus infections and the
tumour development. It is relevant to monitor patients for
CMV, EBV and HHV-8 DNA in patients with rapidly pro-
gressing lymphoma to optimize therapy. It is also a re-
minder of the importance of prevention and prophylaxis
of several infections by having protected sex.
Methods
Analysing (or reading) patient record, Serology test for
human herpesvirus 1-8, PCR tests for human herpes
virus 1-8 on serum and/or plasma samples hematoxylin
staioing and immunohistochemichal staining on lymph-
node, bone marrow, liver biopsy as well as autopsy
material.
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